Qingxiao Yang1, Z Hichen Kang2, Jingze Zhang1, Fuling Qu2, Bin Song3. 1. Neurosurgery Department, Second Hospital of Jilin University, Changchun City, Jilin Province, 130000, China. 2. Rehabilitation Department, Second Hospital of Jilin University, Changchun City, Jilin Province, 130000, China. 3. Neurosurgery Department, Second Hospital of Jilin University, Changchun City, Jilin Province, 130000, China. Email: 15526859189m0@sina.cn.
Research suggests that age is the key factor for the development of acute and chronic
neurodegenerative disorders, such as Alzheimer’s (AD), stroke, and Parkinson’s (PD) diseases
(1). As we know that the aging process occurs on a global scale, the incidence of early
mentioned diseases would be expectable in the near future (2, 3). Moreover, the available
therapies only decelerate disease progression (2). Basic molecular science suggests that
neuronal damage and death are both involved in the molecular mechanism of AD. In
vitro, in vivo, and post-mortem investigations show neuronal
death as a result of the activation of common cell death programs, such as apoptosis (3).
Previous research suggests that the genetic manipulation or pharmacological interventions of
underlying molecular pathways can protect neurons from deadly insults (4). The strategies
for the treatment of neurodegenerative disorders are mainly focused on interrupting,
antagonizing, or slowing the molecular events, leading to the irreversible injury or death
of neurons in neurodegenerative diseases, which are commonly called neuroprotection (5).
Nevertheless, poor translation of rodent investigations into clinical trials has overturned
neurologists and provoked hot debates on the reasons for the apparent failure of
neuroprotection against neurodegenerative diseases (4).AD is considered a wide spread neurodegenerative disease, which affects the cognitive
function of elderly individuals (6). In the course of AD, cortical neuron damage and
disintegration of the hippocampal region cause memory impairment and alter the cognitive
capability (4, 6). The 1st clinical symptoms of AD is characterized by the
demolition of the short-term memory. The pathological hallmark of AD is the presence of
senile plaques, triggering the accumulation of β-amyloid proteins, through the deterioration
of neurofibrillary tangles and neuronal and other proteins (6).Amyloid β peptide (Aβ) has been considered a
possible source of oxidative stress during AD (6,
7). It can generate free radicals that contribute to
the expansion of toxic effects. Previous studies
suggested that Aβ-induced cytotoxicity stimulates the
accumulation of intracellular reactive oxygen species (ROS), finally leading to the peroxidation of membrane
lipids and induced cell death. While the mechanism
of Aβ-induced cytotoxicity is still unknown, previous
investigations indicate that targeting Aβ would be
regarded as a significant neuroprotective approach for
the treatment and prevention of the onset of AD. Several
lines of evidence suggest that antioxidant therapy has
beneficial roles in the treatment of the toxic effects
related to Aβ-induced oxidative stress (6, 8). Due to
the lack of effective treatment for AD, researchers
have focused their research on neuroprotective drugs,
having antioxidant and anti-inflammatory properties.Various efforts have been made in the world to explore
the possible treatment for AD; however, there is no
effective therapy for the cure of AD. Clinical research
suggests that most of the AD patients over the age of
65 suffer from the disease; nevertheless, the symptoms
can occur at the early stages (6). The aetiology of AD
is very complex, and various pathways of neuronal
injury have been proposed (9). According to previous
studies, the cortex, hippocampus, and limbic system
are considered susceptibility regions for the injury
(6, 10). Studies showed that Aβ peptide might be a
possible source for the induction of oxidative stress
in the brain of AD patients (2, 6). It is now known
that it can generate free radical agents that participate
in the expansion of its side/toxic effects. Research
suggests that Aβ-induced cytotoxicity stimulates the
intracellular accumulation of neuronal plaques as a
result of the generation of oxidative stress, ultimately
leading to the peroxidation of lipids and induction of
cell death (2, 6). However, the precise mechanism
underlying the role of Aβ-induced neurotoxicity is still
unclear. The prevention of Aβ accumulation with in the
brain is one of the significant targets for the potential
therapy of AD, as numerous drugs are screened for
this ability as to whether they can halt the onset of the
disease (4, 9). Consequently, the antioxidant therapy
is the best approach for reducing the pathological
conditions and side/toxic effects linked with Aβ-induced oxidative stress. Due to the beneficial effects
of antioxidant compounds, researchers have devoted
themselves to discovering novel phytochemical
agents having antioxidant potential to modulate the
detrimental effects of Aβ-induced neurotoxicity.Isoquercetin (quercetin-3-O-b-D-glucopyranoside) is found in various medicinal and culinary
crops, including fruits, herbs, and vegetables (11). The anti-allergic, antioxidant, and
anti-inflammatory activities of isoquercetin against different rodent models a real ready
documented (12, 13). Paulke et al. (14) showed higher bioavailability of isoquercetin in
comparison with quercetin. To the best of our knowledge, the impact of isoquercetin on the
prevention of cognitive defects occurring in AD patients has not been studied. In the
current experimental study, we aimed to assess the neuroprotective potential of isoquercetin
against the in vitro and in vivo models of AD to explore
the possible mechanism.
Materials and Methods
Chemicals
Dulbecco’s modified Eagle’s medium (DMEM) was
procured from the Thermo Fisher Scientific, Inc, Waltham,
MA, USA.
Cell culture
In this experimental study, the PC12 (phaeochromo-cytoma) cell line was purchased from the Shanghai Biochemistry Co., Ltd (Shanghai, China). High-glucose
DMEM was used for the culture of the cells containing streptomycin (10 U/ml), fetal bovine serum (10%),
and penicillin (100 U/ml). The cells were incubated in
an incubator at 37o
C in a humidified 95% air, 5% CO
atmosphere. When the cells reached 80% confluency,
they were treated with the trypsin (0.25%) and passaged.
Cytotoxicity assay
The method used for the determination of MTT assay was based on a method, as previously
described with minor modifications (15). Briefly, the cells were seeded on to the 96-well
plate at a density of 1×104 cells/plate and further incubated at 37˚C for 24
hours in a CO2 chamber. After 24 hours, the medium was changed with a new
medium, containing different doses of isoquercetin and incubated for 24 hours. After the
incubation period, the medium (containing isoquercetin) was replaced with the MTT (200 μl)
solution and incubated at 37˚C for the next 4 hours. After that the MTT solution was
changed with dimethyl sulfoxide (DMSO) to solubilize the formazan crystals and incubation
for 20 minutes at 37˚C with occasionally shaking, the absorbance of samples was read at
570 nm using a microplate reader (Thermo Scientific Multiscan GO, USA) and the cell
viability was calculated (%).
Nitrite assay
The Griess assay was used for the determination of
nitrite in accordance with a previously described method
with minor modifications (16). Briefly, the cell supernatant
(100 μL) was mixed with the Griess reagent (100 μL),
containing nephtylethylenediamine (0.01%), p-amino-benzene sulphonamide (1%) in phosphoric acid (2.5%
v/v) and kept the reaction mixture in the darkroom for 20
minutes. Finally, the optical absorbance was recorded at
570 nm using a microplate reader.
Estimation of reactive oxygen species generation
The Nitro Blue Tetrazolium (NBT) assay was applied
for the measurement of ROS (16). Briefly, the cells
were incubated with NBT and various concentrations
of isoquercetin for 2 hours in the 96-well plates.
The formazan crystals were solubilised using 2 M
KOH (freshly prepared) in DMSO, and finally, the
absorbance of specimens was monitored at 630 nm
using a microplate reader.
The concentration of malondialdehyde
The concentration of malondialdehyde (MDA) was assayed, as previously described, with
minor modifications (17). Briefly, the cells were seeded in a 6-well plate at a density of
4×105 cells/well and treated with different concentrations of isoquercetin
for 24 hours. Next, the cells were washed with the ice-cold phosphate buffer saline
phosphate buffer saline (PBS) and scrapped in a sodium phosphate solution containing
Triton-X (0.1%). The cells were lysed and finally centrifuged at 10,000 g for 10 minutes.
Afterward, the resulting pellet was discarded, and the supernatant was collected. The cell
supernatant (100 μL) was mixed with trichloroacetic acid (TCA, 10% w/v) and thiobarbituric
acid (TBA, 0.67% w/v) and kept at 95˚C for 1hour. Then, the solution was quickly cooled
and mixed with n-butanol-pyridine (15:1) and centrifuged for 10 minutes at 400 g. The
upper layer (pink) was collected, and the absorbance was read at 532 nm using a microplate
reader.
Determination of glutathione
Indirect estimation of oxidative injury, reduced glutathione (GSH) level was determined
(17) Briefly, PC12 cells at a density (4×105 cells/well) were propagated into
6-well plates and incubated at 37˚C for 24 hours in the CO2 chamber. Afterward,
the cells were treated with the different concentrations of isoquercetin and washed with
the ice-cold PBS and scrapped in sodium phosphate buffer containing Triton-X (0.1%). For
the removal of proteins, the cells were lysed (100 μL) via adding trichloroacetic acid
(10%) and again incubated at 4˚C for 1 hours and finally centrifuged at 5000g rpm for 5
minutes. After that, PBS (100 μl) and DTNB (50 μl) were mixed in the above supernatant (75
μl) and finally estimated the absorbance at 412 nm after the 10 minutes.
Catalase estimation
The method employed for the measurement of the catalase (CAT) enzyme activity was
previously described, with minor modifications (17, 18). Briefly, the cell lysate was
mixed into the hydrogen peroxidase (H2 O2) phosphate buffer
solution in an Eppendorf tube, which was further vortexed and incubated at 37˚C for 3-5
minutes. After that, the resulting solution was mixed with the dichromic acetate solution
and kept for 10 minutes at 100˚C. After that, the reaction mixture was cooled down using
the tap water and centrifuge at 2500 g rpm for 5 minutes and the absorbance of specimens
was read at 570 nm.
Superoxide dismutase activity
The method employed for the measurement of the
superoxide dismutase (SOD) enzyme activity was
previously described, with minor modifications (16-
18). Briefly, cell lysates (100 μM) was mixed with Tris
buffer (1 ml). After that, pyrogallol was mixed, and the
absorbance of the samples was read at 420 nm using a
microplate reader for 5 minutes at a time interval of 1
minute. Finally, the activity of the SOD enzyme was
reported as the percentage of inhibition of pyrogallol
auto-oxidation.
Experimental animals
Swiss Wistar rats (150-180 g, either both sex) were
used for the current protocol. The rats were kept in
the polyethylene cages and kept standard laboratory
conditions, such as temperature (22 ± 2o
C), relative
humidity (45-75%), and light/dark cycle (12/12
hours). The rats received the standard food pellets and
water ad libitum. All the protocol was approved by
The Institutional Ethical Committee (SHJU/19/01/05).
Experimental protocols
For the AD, the rats were grouped into the following
groups, and each group had 12 animals as follows;Normal control group rats (received vehicle only): group IAD control received colchicine (15 µg/5 µl icv): group IIAD control received colchicine (15 µg/5 µl icv) and
Isoquercetin (10 mg/kg): group IIIAD control received colchicine (15 µg/5 µl icv) and
Isoquercetin (20 mg/kg): group IVAD control received colchicine (15 µg/5 µl icv) and
Isoquercetin (40 mg/kg): group VAD control received colchicine (15 µg/5 µl icv) and
Memantine HCL (10 mg/kg): group VIThe rats were intracerebroventricularly infused with
either artificial cerebrospinal fluid. Post-operative
procedures or colchicine (15 Ig) mixed in the ACSF.
After that, the animals were further used for the
determination of neurobehavioral and neuro-chemical
parameters (19).
Post-operative procedures
After the surgery, the rats were kept in the aseptic
condition and received the standard diet (water and
food), and the animals were treated with 5 mg/kg gentamicin (intraperitoneal injection) for the next
three days to prevent the sepsis.
Morris maze test
Morris maze test was used for the estimation of
behavioural effect using the previous method with minor
modifications (19). Briefly, a circular pool (180 cm in
diameter and 60 cm in height) was used for the Morris
maze test. The circular pool filled with the water and the
entire experimental animal put into quadrants during the
acquisition and retention phase (19, 20).
Probe trial
For the probe trial, on the last day of training, the
platform was removed from the pool, and experimental
rats were left free to swim in the pool for the next 2
minutes (19). The time interval of the experimental
animal reached the target quadrant was compared to
other groups, and the data were shown as the latency
time ± standard error means (SEM).
Passive avoidance paradigm
The main purpose of the passive avoidance paradigm
is determination the learning and memory capacity of the
experimental animals (19). Briefly, the experimental rats
were kept in the shuttle box, having 2 compartments (one
for the light, while another for the dark) and unglued with
a guillotine door. During the experiment, the rodent kept
for 30 seconds in the light chamber and the next open a
guillotine door and finally the experimental rodent were
transferred into the dark chamber, and finally, closed the
door for the next 10 seconds.
Neurochemical parameters
At the end of the experimental study, the neurochemical
parameters, including protein carbonyl, acetylcholine
esterase were estimated using the previously published
literature with minor modifications (19).
Antioxidant parameters
Antioxidant enzymes viz., CAT, GSH, lipid peroxidation
(LPO) and SOD were estimated in the hippocampus via
using the previously reported literature (19, 21).
Inflammatory mediators
Pro-inflammatory cytokines like interleukin-1β (IL-1β), IL-6 and tumour necrosis factor-α (TNF-α) and
inflammatory mediator including nuclear transcription
factor (NF-κB), was estimated using standard kits.
Statistical analysis
One-way analysis of variance (ANOVA) was used for
the determination of statistical significance. The difference
between the examined and control cells was analysed using the post hoc Newman-Kuels test, and the values are
presented as mean ± SEM. P<0.05 was considered as a
statistically significant value.
Results
Effect of isoquercetin on cell viability
Figure 1 exhibited the effect of isoquercetin on
cell viability. Figure 1 exhibited that the isoquercetin
100 μM was found to be non-toxic as they did not
induce any considerable alteration in the growth of
PC12 cells. Moreover, isoquercetin dose up to 100
μM exhibited a sign of cytotoxicity with considerable
change. Accordingly, isoquercetin at a dose range of
25-100 μM is a safe drug and can be used for further
experimental analyses.The cell viability effect of isoquercetin on P12 cells. ns; Non
significant, IQ; Isoquercetin, and *; P<0.05.
Effect of isoquercetin on lipopolysaccharide induced
nitrosative stress
It is well known that during the oxidative stress
increased the nitrosative stress due to the generation of
free radicals. A similar result was found in the current
experimental study. PC12 cells were treated with
lipopolysaccharide (LPS, 100 ng/mL) and showed the
increased level of nitrite released into the supernatant (24
hours) as compared to the control. Isoquercetin treatment
significantly (P<0.05) reduced the release of nitrite into
the supernatant in a dose-dependent manner as compared
to the LPS-stimulated cells (Fig.2A).
Fig.2
Effect of isoquercetin on the LPS induced nitrite and ROS activity in PC12 cells. A.
Nitrite and B. ROS as described in the material and methods.
Values are presented as mean ± SEM. ### showed the significance as compared
to the control group (P<0.001). * demonstrates the significance as compared to
LPS-induced group (*; P<0.05, **; P<0.01, and ***; P<0.001). LPS;
Lipopolysaccharide, IQ; Isoquercetin, and ROS; Reactive oxygen species.
Effect of isoquercetin on lipopolysaccharide induced
reactive oxygen species level
During AD, the ROS level considerably increased
due to the generation of free radicals. PC12 cells
treated with the LPS (100 ng/mL) considerably
(P<0.001) boosted the production of ROS as compared
to the normal cells. The concentration-dependent treatment of isoquercetin significantly (P<0.001)
down-regulated the production of ROS as compared to
the LPS treated cells (Fig.2B).Effect of isoquercetin on the LPS induced nitrite and ROS activity in PC12 cells. A.
Nitrite and B. ROS as described in the material and methods.
Values are presented as mean ± SEM. ### showed the significance as compared
to the control group (P<0.001). * demonstrates the significance as compared to
LPS-induced group (*; P<0.05, **; P<0.01, and ***; P<0.001). LPS;
Lipopolysaccharide, IQ; Isoquercetin, and ROS; Reactive oxygen species.
Effect of isoquercetin on lipopolysaccharide induced
antioxidant enzymes
LPS (100 ng/mL) treatment demonstrated the increased
level of MDA as compared to healthy control cells.
Isoquercetin treatment significantly (P<0.001) decreased
the level of MDA as a dose-dependent manner as
compared to LPS control cell lines (Fig.3A).
Fig.3
Effect of isoquercetin on the LPS induced antioxidant activity in PC12 cells. A.
GSH, B. MDA, C. CAT and D. SOD as
described in the material and methods. Values are presented as mean ± SEM.
### showed the significance as compared to the control group (P<0.001).
* demonstrates the significance as compared to LPS-induced group (*; P<0.05,
**; P<0.01, and ***; P<0.001). LPS; Lipopolysaccharide, GSH;
Glutathione, MDA; Malondialdehyde, CAT; Catalase, SOD; Superoxide dismutase, and IQ;
Isoquercetin.
In the level of SOD, CAT and GSH, LPS (100 ng/
mL) treatment significantly (P<0.001) showed the
reduced level as compared to normal cell lines, and
the concentration-dependent treatment of isoquercetin
exhibited the increased level of SOD (Fig.3B), CAT
(Fig.3C) and GSH (Fig.3D) as compared to the LPS
control cell lines.Effect of isoquercetin on the LPS induced antioxidant activity in PC12 cells. A.
GSH, B. MDA, C. CAT and D. SOD as
described in the material and methods. Values are presented as mean ± SEM.
### showed the significance as compared to the control group (P<0.001).
* demonstrates the significance as compared to LPS-induced group (*; P<0.05,
**; P<0.01, and ***; P<0.001). LPS; Lipopolysaccharide, GSH;
Glutathione, MDA; Malondialdehyde, CAT; Catalase, SOD; Superoxide dismutase, and IQ;
Isoquercetin.
Effect of isoquercetin on lipopolysaccharide induced
pro-inflammatory cytokines
Figure 4 showed the effect of isoquercetin and LPS
on the pro-inflammatory cytokines on the PC12 cells.
LPS (100 ng/mL) showed the significantly (P<0.001)
increased the level of pro-inflammatory cytokines such as
IL-1β, IL-6, IL-8, and TNF-α as compared to the control
cell lines. The dose-dependent treatment of isoquercetin
significantly (P<0.05) reduced the level of pro-inflammatory cytokines, including IL-1β (Fig.4A), IL-6
(Fig.4B), IL-8 (Fig.4C) and TNF-α (Fig.4D) as compared
to the LPS induced control cell lines.
Fig.4
Effect of isoquercetin on the LPS induced pro-inflammatory cytokines parameter in PC12 cells.
A. IL-1β, B. IL-6, C. IL-8 and
D. TNF-α as described in the material and methods. Values are presented as
mean ± SEM. ### showed the significance as compared to the control group
(P<0.001). * demonstrates the significance as compared to LPS-induced group (*;
P<0.05, **; P<0.01, and ***; P<0.001). LPS; Lipopolysccahride,
IQ; Isoquercetin, IL-8; Interleukin-8, and TNF-α; Tumor necrosis factor-α.
Effect of isoquercetin on the LPS induced pro-inflammatory cytokines parameter in PC12 cells.
A. IL-1β, B. IL-6, C. IL-8 and
D. TNF-α as described in the material and methods. Values are presented as
mean ± SEM. ### showed the significance as compared to the control group
(P<0.001). * demonstrates the significance as compared to LPS-induced group (*;
P<0.05, **; P<0.01, and ***; P<0.001). LPS; Lipopolysccahride,
IQ; Isoquercetin, IL-8; Interleukin-8, and TNF-α; Tumor necrosis factor-α.
Time spent in the platform quadrant
The probe trial data analysis was performed in
experimental rats. Colchicine-treated rats exhibited
a significantly decreased latency towards the target
quadrant as compared with the spend time by the control
group. Moreover, such down-regulation in the time spent
in the quadrant was enhanced upon the treatment with
isoquercetinin a dose-dependent manner. A similar results
were obtained in the memantine-treated group (Fig.5).
Fig.5
Effect of isoquercetin on the colchicine impaired spatial memory
and learning in rats appraises via probe trial in water maze; data shows
mean ± SEM of 6 rats in each group. Significant difference represent as
compared to colchicine control group rats (**; P<0.01 and ***; P<0.001).
IQ; Isoquercetin and MM; Memantine.
Effect of isoquercetin on the colchicine impaired spatial memory
and learning in rats appraises via probe trial in water maze; data shows
mean ± SEM of 6 rats in each group. Significant difference represent as
compared to colchicine control group rats (**; P<0.01 and ***; P<0.001).
IQ; Isoquercetin and MM; Memantine.
Effect of isoquercetin on memory and learning via
passive avoidance paradigm
The passive avoidance paradigm was used for the estimated effect of isoquercetin on the
memory and learning capacity of the rats. Colchicine induced rats exhibited brain damage
as compared to the control group rats. Figure 6 showed that the reduced transfer latency
time as compared to the acquisition trial transfer latency time from the control group to
the colchicine-treated group (3rd retention trial). The isoquercetin-treated
group exhibited the increased transfer latency time as compared with the acquisition
trial. On the other hand, the standard drug-treated group showed the increased transfer
latency time as compared to the acquisition trial. Moreover, instantaneous isoquercetin
received rats exhibited a significant enhance in TLT in retention trials in comparison
with the acquisition trial transfer latency time.showed the effect of isoquercetin and colchicine on passive
avoidance response; data shows mean ± SEM of 6 rats in each group.
Significant difference represent as compared to colchicine control group
rats (*; P<0.05, **; P<0.01, and ***; P<0.001). IQ; Isoquercetin and MM;
Memantine
Effect of isoquercetin on brain-derived neurotrophic
factor
Figure S1 (See Supplementary Online Information at
www.celljournal.org) showed the effect of isoquercetin on
the level of brain-derived neurotrophic factor (BDNF) in
colchicine induced group rats. Colchicine induced group
rats exhibited a reduced level of BDNF in comparison
to normal control. Colchicine-induced group exhibited
a significantly (P<0.001) increased level of BDNF in a
dose-dependent manner. On the contrary, Memantine
significantly (P<0.001) enhanced the level of BDNF,
but the level was slightly lower as compared to the
isoquercetin (40 mg/kg) treated drugs.
Effect of isoquercetin on Aβ peptide activity
During the colchicine induced AD, the level of Aβ peptide
activity considerably boosted and reached almost 2-3 times
as compared to the normal control. A similar result was
obtained in the colchicine induced treated group rats. The
level of Aβ peptide activity reached almost 4 times more as
compared to normal control. The dose-dependent treatment
of isoquercetin treatment significantly (P<0.001) down-regulated the level of Aβ peptide activity as compared to the
colchicine induced group rats. Standard drug (memantine)
treated group rats showed the reduced level of Aβ peptide
activity as compared to the colchicine induced group rats
(Fig.S2) (See Supplementary Online Information at www.
celljournal.org).
Effect of isoquercetin on acetylcholinesterase activity
Figure S3 (See Supplementary Online Information at www.
celljournal.org) demonstrated the effect of isoquercetin on the
level of acetylcholinesterase (AchE) on the colchicine induced
group rats. Colchicine-induced group showed the reduced
activity of AchE, while the dose-dependently treatment of
isoquercetin and standard drug (memantine) significantly
(P<0.001) increased the activity of AchE.
Effect of isoquercetin on P. carbonyl activity
Figure S4 (See Supplementary Online Information at
www.celljournal.org) illustrated the effect of isoquercetin
on the level of P. carbonyl activity. Colchicine induced
group rats showed the increased activity of P. carbonyl
activity and dose-dependently treatment of isoquercetin
and standard drug (memantine) significantly (P<0.001)
decreased the activity of P. carbonyl activity.
Effect of isoquercetin on pro-inflammatory cytokines
Figure S5 (See Supplementary Online Information at
www.celljournal.org) showed the effect of isoquercetin on
the level of pro-inflammatory cytokines in the colchicine
induced AD rats. Colchicine induced group rats showed
an increased level of pro-inflammatory cytokines, such as
TNF-α, IL-1β, and IL-6 and dose-dependent treatment of
isoquercetin significantly (P<0.001) reduced the level of
pro-inflammatory cytokines.
Effect of isoquercetin on NF-κB activity
The level of NF-κB considerably boosted during AD.
A similar result was obtained in the colchicine induced
AD control group rats. The dose-dependent treatment of
isoquercetin significantly (P<0.001) reduced the level
of NF-κB as compared to the colchicine induced AD
control group rats (Fig.S6) (See Supplementary Online
Information at www.celljournal.org).
Fig.6
showed the effect of isoquercetin and colchicine on passive
avoidance response; data shows mean ± SEM of 6 rats in each group.
Significant difference represent as compared to colchicine control group
rats (*; P<0.05, **; P<0.01, and ***; P<0.001). IQ; Isoquercetin and MM;
Memantine
Discussion
In the year of 1976, PC12 cell lines have been considered as the significant model system
for neurochemical and neurobiological investigations, as its adaptability, comfort culture,
and huge information of their differentiation and proliferation (19). In the current
investigation, we used the PC12 cells to investigate the neuroprotective effect of
isoquercetin. In an in vitro model, PC12 cells were treated with the LPS,
which is commonly present in the Gram-Negative bacteria membrane (22). By scrutinizing the
apoptosis, cell viability, antioxidant and pro-inflammatory cytokines, we established the
cell model of LPS was successfully constructed (23). It is well defined that oxidative
stress plays an important mechanism underlying PC12 induced neurotoxicity during AD (24).
Consequently, targeting oxidative stress is the best approach to treat A0. In the current
experimental study, we established the LPS induced oxidative model in the PC12 cells. LPS
significantly increased the level of MDA (LPO parameter) and intracellular formation of ROS
and reduced the levels of SOD, CAT in the PC12 cells as compared with the non-stimulated
cells, approaching the pathophysiological condition of oxidative stress during the central
nervous system (CNS) disorders. Isoquercetin treatment significantly reduced the
intracellular ROS generation, MDA level, and nitrite release and increased the activity of
SOD, GSH, and CAT, suggesting the antioxidant role and maintain the intracellular oxidative
stress and consequent neuroprotection. On the basis of the results, isoquercetin could be
useful for the treatment of neuro-inflammatory diseases like AD, multiple sclerosis, PD etc.Neurodegenerative disease such as AD is considered as the age-related disease (25). It is
related to the early phase of cognitive dysfunction linked with behavioural and social
deterioration. The feature of AD is extracellular senile plaques, loss of neurons,
intracellular neurofibrillary in the region of brain, such as hippocampus region (6).
Previous research suggests that the hippocampus region of the brain is the primary target,
which involved in AD pathophysiology (6, 9). It is well known that the accumulation of β
amyloid and the generation of amyloid plaques are the hallmarks of AD (6, 26). In the
current protocol, we made an attempt to scrutinize the neuroprotective effect of
isoquercetin against the in vitro and in vivo model of AD
and explore the possible mechanism of action.For the learning and memory impairment, colchicine
induced AD model is commonly used (27). Colchicine
induced the dysfunction in various parts of the
brain, especially when inducing the severity into the
hippocampus region of the brain. It is well known that
the level of AChE was reduced during the impaired
learning and memory capacity of rodents (28). A similar
result was found in the colchicine-induced group; a
marked reduced AChE content was observed, while the
dose-dependent treatment of isoquercetin significantly
increased the AChE content and suggests the memory and
learning improvement. Previous research suggests that
the marked increase in the activity of AChE and decrease
the activity of choline acetyltransferase showed a reduced
level of Ach (29). Various experimental study suggests
that the decreased level of AChE activity, indicating
the impairment of cognitive function and improved
the activity of AChE suggests the increase cognitive
function (27). Other parameters such as Aβ start the
deposition during the AD in the cerebral area of the brain,
and it induces the memory dysfunction with marked
cholinergic function (30)bisdemethoxycurcumin and
demethoxycurcumin. During AD, the accumulation of Aβ
considerably increased and induced memory dysfunction.
In the current experimental study, the content of Aβ was considerably boosted and dose-dependent treatment of
isoquercetin significantly reduced the content of Aβ.
A similar momentum was observed in the memantine
induced group rats.Previous research suggests that the colchicine
administration exhibit the dose- and time-dependent
behavioural, neurochemical, anatomical changes, and
the changes reached upwithin 2-3 weeks (27). Colchicine
(tubulin inhibitor), avoids microtubule assembly inducing
synaptic loss and neurofibrillary degeneration that take
part in the diminishing of intracellular trafficking of
neurotrophic factors, oxidative stress, inflammation,
and axonal excitotoxicity (31). Colchicine also
disrupts the cytoskeleton that has to be linked with the
neurodegeneration in AD and also executing a deadly
effect on the activity and persistence of neurons (19).
Meanwhile, colchicine administration does not produce
a significant alteration in the gross locomotor and
behavioural activities in rats. The current experimental
study showed that the open field did not show higher
scores for the locomotor and behavioural activities in
each rat.Previous research suggests that the BDNF is the main
target in the pathophysiology of various neurodegenerative
diseases (19). BDNF is considering as the prognostic and
diagnostic biomarker of AD. During the AD, the level of
BDNF considerably reduced in the rodent model when
treated with colchicine, and it might take part in the
reduction of the hippocampus region of the brain linked
with the age-related memory decline in the late adulthood
(32). Studies suggest that the BDNF gene is related to
the late onset of AD. To identify the pathophysiology
of the neurodegenerative disease, the rodent model is
the crucial tool, and most of researchers used the animal
models for elucidation of the neurological disease
pathophysiology (33, 34). One of these experimental
models, central injection of colchicine, was injected into
the lateral ventricles, which is measured as appropriate
cases of sporadic dementia of Alzheimer’s in humans.
During the AD, the level of BDNF was considerably
reduced in the hippocampal tissue as compared to
the untreated rats and dose-dependently treatment of
isoquercetin significantly increased the level of BDNF
suggesting the neuroprotective effect via neurotrophin
induction. Therefore, the ultimate goal of the current
study was elucidating the possible neuroprotective effect
of isoquercetin in the animal model of AD disease and
explore the possible underlying mechanism.During the inducing the colchicine intracerebroventricular (icv), its start the reduction
of BDNF level into the hippocampal tissue, decreased the level of Aβ peptide level into the
hippocampal tissue as well as down-regulated the antioxidant enzymes, these parameter
suggesting that the colchicine injection deteriorates the memory and learning ability (34,
35) and its also induces the oxidative stress, boost the inflammatory reaction as well as
induces the injury in the central neuronal. Restoration of these enzymes and parameters via
isoquercetin suggesting the neuroprotective effect via enhancing the cognitive function.
Definitely, this current experimental study showed the significant memory dysfunction in the
Morris water maze test, as confirmed by considerably enhanced the initial acquisition
latency, as well as 1st and 2nd retention latencies.Previous research suggests that the oxidative stress
play a significant role in the expansion of AD (34, 35).
Various studies suggest that oxidative stress related to
ROS generation and take widely precipitation during the
neurological and psychiatric disorder. During the induction
of oxidative stress, frequently observed the imbalance
between the pro-oxidant and endogenous antioxidant
and its can be estimated via measured the redox state in
the plasma. Endogenous antioxidant parameters such as
SOD, CAT and GSH play a significant role to scavenge
the free radicals (35, 36). During the colchicine induced
AD, the level of free radical increase due to the induction
of oxidative stress and reduced the level of endogenous
antioxidant mechanism via increased the peroxidation
(36, 37). CAT and SOD are considered as the first line
antioxidant and both endogenous antioxidants scavenge
the free radical especially the hydroxyl radicals (37, 38).
Another antioxidant malonaldehyde (MDA) is the marker
of lipid peroxidation and its take part in the oxidative
stress and its also consider as the end product of the
polyunsaturated fatty acid (PUFA) lipid peroxidation.
The level of MDA significantly increased during the
oxidative stress and its consider as the significant marker
to estimate the oxidative stress throughout the body (37).
During the experimental protocol, colchicine induced AD
rats showed the increased level of MDA and isoquercetin
significantly reduced the level of MDA at dose dependent
manner. In the current protocol, the up-regulation of MDA
and protein carbonyls level and down-regulation of CAT,
GSH and SOD level were observed and dose dependent
treatment of isoquercetin significantly reduced the level of
MDA, protein carbonyls and increased the level of CAT,
GSH and SOD, which suggest the reduction of oxidative
stress in the brain. Result suggests the neuroprotective
effect of isoquercetin via antioxidant nature.Another factor of AD pathogenesis, inflammatory,
and oxidative stress may take part in the expansion of
the disease. The presence of the NF-κB was thefirsttime
recognized in the nuclear B cell. NF-κB is the significant
transcription factor, which contributes to the activation
of genes that are involved in the generation of pro-inflammatory cytokines and induces neuroinflammation
in AD. Several references suggest that the NF-κB, having
the ability to merge the sequence-specific enhances of
the immunoglobulins K light chain gene. During the
generation of AD, the NF-κB level was increased in
the senile plaques. Various research suggests that the
activation of NF-κB and NF-κBp65 either directly or
indirectly associated with the severity of AD and targeting
the NF-κB is the best approach to treat AD. Isoquercetin
already reported to reduce the NF-κB activation in the
tumour cells and also induce the anti-inflammatory effect via suppressing the NF-κB activation in the lymphocytes
(32). NF-κB activates pro-inflammatory cytokines
such as IL-1β, IL-6, and TNF-α, which take part in the
expansion or progression of inflammatory disease. It is
well documented that neuro-inflammation play a crucial
role in the expansion of neurodegenerative diseases, such
as AD. Neuro-inflammation is involved in the microglial
cells activation and also takes part in the participation
of astrocytes and neurons. Recent research suggests that
the pro-inflammatory cytokines such as IL-1β, IL-6, and
TNF-α activate neuroinflammation and start the cognitive
function destruction (27). Previous research suggests that
the continuous generation of pro-inflammatory cytokines
leads to the impairment of cognitive function in the brain.
TNF-α, secrete from the plaques during the AD disease
and also boost the secretion of IL-1β from the central
nervous system. The up-regulation of IL-1β level in the
hippocampus region showed the interfering of long-term potentiating that induce cognitive impairment (21,
26, 27). It also induced the suppression of the long-term
potentiating, inducing the synaptic plasticity dysfunction
in the hippocampus region of the brain. IL-1β also reduces
the level of BDNF, which is indirectly reduced by LTP and
also causes cognitive dysfunction. It is well documented
that enhanced levels of pro-inflammatory cytokines, such
as TNF-α and IL-1β in the hippocampus region of the
brain are responsible for the dysfunction of postoperative
cognitive (8). In the current protocol, isoquercetin
significantly reduced the level of pro-inflammatory
cytokines and suggestion the anti-inflammatory effect.Previous research suggests that oxidative stress plays a
significant role in the expansion of AD. Various studies
suggest that oxidative stress and ROS generation are
evident during the neurological and psychiatric disorders.
Continuous generation of oxidative stress can induce
apoptosis and cell death. During the induction of oxidative
stress, frequently observed the imbalance between the
pro-oxidant and endogenous antioxidants, and it could
be estimated via measuring the redox state in the plasma.
CAT and SOD are considered the first-line antioxidants,
and the both endogenous antioxidants scavenge the
free radicals, especially hydroxyl radicals (37, 38). The
endogenous antioxidants, such as SOD, CAT, and GSH
play a significant role in scavenging the free radicals
(39, 40). During colchicine-induced AD, the level of
the free radicals are increased due to the induction of
oxidative stress and reduced the level of the endogenous
antioxidant mechanism via increasing the peroxidation
(38, 39). Another antioxidant MDA is the marker of lipid
peroxidation, and it participates in oxidative stress, and it
is also considered the end-product of the polyunsaturated
fatty acid (PUFA) lipid peroxidation. The level of MDA
significantly increased during the oxidative stress and it
is considered a significant marker to estimate oxidative
stress throughout the body (27). During the experimental
protocol, colchicine-induced AD showed an increased
level of MDA, while isoquercetin significantly reduced
the level of MDA in a dose-dependent manner. In the
current protocol, the up-regulation of MDA and protein carbonyls level and down-regulation of CAT, GSH, and
SOD level were observed. The dose-dependent treatment
of isoquercetin significantly reduced the level of MDA,
protein carbonyls, and it increased the level of CAT, GSH,
and SOD, suggesting the reduction of oxidative stress in
the brain. The results suggest the neuroprotective effect of
isoquercetin via antioxidant nature.
Conclusion
Isoquercetin did not demonstrate the impact of cell viability on the PC12 cells. PC12 cells
treated with LPS had increased nitrile, and ROS levels, and the dose-dependent isoquercetin
treatment reduced the level of oxidative stress. The dose-dependent treatment of
isoquercetin significantly altered the antioxidant, and pro-inflammatory parameter.
Colchicine decreased the latency period and significantly increased the latency time and
dose-dependent treatment of isoquercetin in the in vivo experimental study.
Colchicine-induced group rats decreased levels of BDNF and AchE, while significantly
increased levels of Aβ-peptide, P. carbonyl and dose-dependent isoquercetin treatment
increased levels of BDNF, AchE and decreased levels of Aβ-peptide, P. carbonyl.
Colchicine-induced group rats increased the level of pro-inflammatory cytokines and
inflammatory mediators and significantly reduced the level of pro-inflammatory cytokines and
inflammatory mediators through dose-dependent isoquercetin treatment. The result showed that
isoquercetin significantly altered cognitive function and prevented neurochemical and
neurobehavioral alteration against colchicine by inducing rats of AD through the antioxidant
and anti-inflammatory mechanism.
Authors: H Frank; T Zilker; M Kirchmair; F Eyer; B Haberl; G Tuerkoglu-Raach; M Wessely; H-J Gröne; U Heemann Journal: Clin Nephrol Date: 2009-05 Impact factor: 0.975